Important note

This AI stock analysis for Mirum Pharmaceuticals is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Mirum Pharmaceuticals - AI Stock Analysis

Analysis generated March 20, 2025

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for rare liver diseases. With a pipeline that includes treatments for cholestatic liver diseases, Mirum aims to address unmet medicinal needs in the child and adult population. The company's flagship product, Maralixibat, has shown promising clinical results, contributing significantly to its revenue generation and business outlook.

Fundamental Analysis

Revenue for the last quarter was $89 million. This is an increase of 14.18% compared to the previous quarter, marking positive sequential growth. Compared to the same quarter last year, there is a significant increase of 87.28%, highlighting robust year-over-year performance. These numbers demonstrate strong revenue growth and effective market penetration.

Net income for the last quarter was $14 million, marking a 42.22% increase sequentially and a 39.65% increase compared to the same quarter last year. This indicates that the company is not only increasing its revenue but also improving its profitability metrics.

EBITDA for the last quarter was $6.8 million, marking a robust 63.39% increase compared to the previous quarter and a 69.91% increase year-over-year. This suggests that the company is managing its operating costs efficiently while scaling its operations.

However, recent insider selling is a red flag that could indicate potential concerns from those with intimate knowledge of the company's operations. Such moves are often seen as bearish signals by investors.

Technical Analysis

Today's stock price is $47.87, which is a 9.95% decrease from a month ago, raising short-term concerns. However, compared to a year ago, the stock price has increased by 83.83%, suggesting a strong long-term bullish trend.

The current Simple Moving Average over 10 days (SMA10) is $45.10, up from the previous SMA10 of $44.61. This indicates a potential upward trend in price movement, implying bullish sentiment in the near term.

The Relative Strength Index (RSI) is 38.7, indicating a neutral condition. An RSI value below 30 is generally considered oversold, and above 70 is considered overbought, so a neutral RSI suggests balanced market conditions.

Alternative Data Analysis

Starting with job postings and employee sentiment, Mirum Pharmaceuticals has 10 open positions, down by 9% in the last couple of months. This may indicate cost-cutting measures, a concerning sign for a growing company.

The business outlook among employees at Mirum Pharmaceuticals is neutral, which could suggest neither optimistic nor pessimistic future expectations.

In terms of customer acquisition, Mirum Pharmaceuticals has an estimated 6,000 visitors to their webpage, down by 25% in recent months. This signifies a troubling decline that could imply a loss in customer engagement or interest.

Additionally, the company has 400 Instagram followers, up by 6%, and 590 Twitter followers, up by 4%, indicating some positive social media engagement.

Lastly, the AI score from AltIndex is 68, indicating a buy signal based on a combination of fundamental, technical, and alternative data analysis.

Conclusion

In conclusion, Mirum Pharmaceuticals presents a mixed but generally positive outlook. The company demonstrates significant growth in revenue, net income, and EBITDA, backed by a strong year-over-year stock price increase. Technical indicators like the SMA10 point towards a potential upward trend, though a neutral RSI indicates balanced conditions. Alternative data presents a mixed picture, with decreasing web traffic but increasing social media engagement. Despite some recent insider selling and a slight reduction in job postings, the AltIndex AI score suggests a buy signal. The recommendation is to consider Mirum Pharmaceuticals stock as a potentially valuable addition to a diversified investment portfolio.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.